BIM

115.5

+1.49%↑

SRT3

228.3

-0.7%↓

GXI

55.3

+2.88%↑

ICAD

21.08

-0.57%↓

BIM

115.5

+1.49%↑

SRT3

228.3

-0.7%↓

GXI

55.3

+2.88%↑

ICAD

21.08

-0.57%↓

BIM

115.5

+1.49%↑

SRT3

228.3

-0.7%↓

GXI

55.3

+2.88%↑

ICAD

21.08

-0.57%↓

BIM

115.5

+1.49%↑

SRT3

228.3

-0.7%↓

GXI

55.3

+2.88%↑

ICAD

21.08

-0.57%↓

BIM

115.5

+1.49%↑

SRT3

228.3

-0.7%↓

GXI

55.3

+2.88%↑

ICAD

21.08

-0.57%↓

Search

Pharma Mar SA

Ouvert

73.25 -9.57

Résumé

Variation du prix de l'action

24h

Actuel

Min

72

Max

80.3

Chiffres clés

By Trading Economics

Revenu

5.7M

9.5M

Ventes

2.7M

48M

P/E

Moyenne du Secteur

50.302

57.333

BPA

1.063

Rendement du dividende

0.87

Marge bénéficiaire

19.737

Employés

500

EBITDA

8.2M

15M

Recommandations

By TipRanks

Recommandations

Achat

Prévisions sur 12 Mois

+33.67% upside

Dividendes

By Dow Jones

Rendement du dividende

Moyenne du Secteur

0.87%

2.63%

Prochains Résultats

30 avr. 2025

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

-91M

1.3B

Ouverture précédente

82.82

Clôture précédente

73.25

Score Technique

By Trading Central

Confiance

Very Strong Bullish Evidence

Pharma Mar SA Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

24 avr. 2025, 23:54 UTC

Actions en Tendance

Stocks to Watch: Alphabet, Intel, AppFolio

24 avr. 2025, 23:51 UTC

Market Talk

Gold Edges Higher, Supported by U.S. Dollar Weakness -- Market Talk

24 avr. 2025, 23:46 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

24 avr. 2025, 23:46 UTC

Market Talk

Nikkei May Rise on Hopes for Easing U.S.-China Trade Tensions -- Market Talk

24 avr. 2025, 23:37 UTC

Actualités

Big Tech Braces for Tariff-Induced Advertising Slowdown -- WSJ

24 avr. 2025, 23:36 UTC

Actualités

Tokyo Consumer Inflation Accelerates in April as Companies Raise Prices

24 avr. 2025, 23:13 UTC

Actualités
Résultats

Google's Earnings Power Holds Up in Global Turbulence -- Update

24 avr. 2025, 23:09 UTC

Actualités

Trump Initiatives Knocked Back in a New Round of Court Rulings -- 2nd Update

24 avr. 2025, 23:02 UTC

Acquisitions, Fusions, Rachats

SK Telecom to Sell 10.8M Kakao Shares via After-Hours Block Trading

24 avr. 2025, 23:02 UTC

Acquisitions, Fusions, Rachats

SK Telecom to Dispose of 2.4% Stake in Kakao to Raise KRW413.27B

24 avr. 2025, 22:51 UTC

Actualités
Acquisitions, Fusions, Rachats

Germany's Merck Nears Roughly $3.5 Billion Deal for SpringWorks -- Update

24 avr. 2025, 22:48 UTC

Actualités

Walmart Walks the DEI Tightrope in Latest Proxy Statement -- Barrons.com

24 avr. 2025, 22:47 UTC

Market Talk

Intel Remains in Tough Position, CFRA Research Analyst Says -- Market Talk

24 avr. 2025, 22:38 UTC

Market Talk
Résultats

Tariffs Hurt Intel's 2Q Outlook as CFO Warns Economic Slowdown is Likely -- Market Talk

24 avr. 2025, 22:24 UTC

Résultats

Aluminum Corp. of China: Increase in Product Sales Supported 1Q Results >2600.HK

24 avr. 2025, 22:24 UTC

Résultats

Aluminum Corp. of China 1Q Rev CNY55.78B Vs. CNY48.96B >2600.HK

24 avr. 2025, 22:24 UTC

Market Talk
Résultats

Intel's Comeback Involves More Engineers, More In-Office Work -- Market Talk

24 avr. 2025, 22:23 UTC

Résultats

Aluminum Corp. of China 1Q Net CNY3.54B Vs. Net CNY2.23B >2600.HK

24 avr. 2025, 22:11 UTC

Market Talk
Résultats

Global Equities Roundup: Market Talk

24 avr. 2025, 22:11 UTC

Market Talk
Résultats

Intel CEO: Layoffs Will Simplify Company Structure -- Market Talk

24 avr. 2025, 22:09 UTC

Actualités
Résultats

Intel Cuts Outlook, Says Layoffs Are in Store -- Update

24 avr. 2025, 22:00 UTC

Market Talk
Résultats

T-Mobile's Key Subscriber Metric Disappoints Despite Earnings Beat -- Market Talk

24 avr. 2025, 21:39 UTC

Actualités

Trump Initiatives Knocked Back in a New Round of Court Rulings -- WSJ

24 avr. 2025, 21:24 UTC

Actualités
Résultats

Bristol Myers Reports Better-Than-Expected Earnings. The Future Is Cloudy. -- Barrons.com

24 avr. 2025, 21:24 UTC

Actualités
Résultats

Google's Earnings Power Holds Up in Global Turbulence -- WSJ

24 avr. 2025, 21:23 UTC

Actualités
Résultats

Intel Cuts Outlook, Says Layoffs Are in Store -- WSJ

24 avr. 2025, 21:04 UTC

Résultats

T-Mobile Reports Strong Earnings but Its Wireless Results Disappoint. The Stock Is Sliding. -- Barrons.com

24 avr. 2025, 21:03 UTC

Résultats

Agnico-Eagle Mines Believes Its Rev Structure Will Be Largely Unaffected by the Tariffs >AEM.T

24 avr. 2025, 21:03 UTC

Résultats

Agnico-Eagle Mines Total Expected Capex for 2025 Still Estimated at $1.75 B to $1.95 B >AEM.T

24 avr. 2025, 21:02 UTC

Résultats

Agnico-Eagle Mines Positioned to Achieve 2025 AISC Per Ounce Guidance of $1,250 to $1,300. >AEM.T

Comparaison

Variation de prix

Pharma Mar SA prévision

Objectif de Prix

By TipRanks

33.67% hausse

Prévisions sur 12 Mois

Moyen 108.002 EUR  33.67%

Haut 108 EUR

Bas 108 EUR

Basé sur 1 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

1 ratings

1

Achat

0

Maintien

0

Vente

Score Technique

By Trading Central

76.35 / 81.4Support & Résistance

Court Terme

Very Strong Bullish Evidence

Moyen Terme

Very Strong Bearish Evidence

Long Terme

Bullish Evidence

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Pharma Mar SA

Pharma Mar, S.A., a biopharmaceutical company, engages in the research, development, production, and commercialization of bio-active principles for the use in oncology in Spain, Italy, Germany, Ireland, France, rest of the European Union, the United States, and internationally. The company operates through Oncology and RNA Interference segments. It develops and commercializes Yondelis for the treatment of soft tissue sarcoma and for ovarian cancer; Aplidin for treating R/R multiple myeloma; and Zepzelca to treat patients with small cell lung cancer. The company develops Ecubectedin (PM14), which is in phase II clinical trials for the treatment of solid tumors, as well as in Phase I clinical trials for the treatment of soft tissue sarcoma and prostate cancer; PM534 that is Phase I clinical trials for treating solid tumors; PM54, which is in Phase I clinical trials for the treatment of solid tumors; SYL1801 that is in phase II clinical trials for treating macular degeneration; SYL116011, which is in preclinical studies for the treatment of ocular allergies; and SYL A and B that is in investigational studies to treat retinitis pigmentosa. In addition, it engages in the research, development, production, and sale of products with therapeutic activity based on reducing or silencing gene expression. Pharma Mar, S.A. was incorporated in 1986 and is based in Madrid, Spain.